title: Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamil.
abstract: An open-label, multicenter, dose-titration study evaluated 2,556 patients with stage I or II essential hypertension (untreated or previously treated with one antihypertensive agent) to assess the effect of a chronotherapeutic formulation of verapamil (Verelan PM) designed to provide maximum plasma concentrations in the midmorning hours. After starting with 200 mg/d at bedtime, the dose of Verelan PM was titrated to a maximum of 400 mg/d at 4-week intervals to achieve a target blood pressure (BP) <140/90 mm Hg using morning BP measurements. In 85.3% of patients, a diastolic blood pressure (DBP) response to less than 90 mm Hg or a 10-mm Hg decline from baseline DBP was achieved. The systolic BP response (<140 mm Hg or 10% decline from baseline) was attained in 76.9% of patients. Blood pressure was controlled in 62.6% of patients with Verelan PM monotherapy. Upward titration of Verelan PM from 200 to 400 mg nearly doubled the DBP response rate (45.8% to 85.3%). This chronotherapeutic formulation of verapamil was well tolerated in this community trial.
authors.affiliation: Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, GA 30912-3105, USA. mprisant@mail.mcg.edu
authors.forename: L Michael
authors.initials: LM
authors.lastname: Prisant
authors.forename: Henry R
authors.initials: HR
authors.lastname: Black
authors.forename: Franz
authors.initials: F
authors.lastname: Messerli
authors.forename: Michael
authors.initials: M
authors.lastname: Weber
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013810:Therapeutic Equivalency; D014700:Verapamil / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D002121:Calcium Channel Blockers; D014700:Verapamil